NCT05458258Completed
Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia
Investigating The Prognostic Significance Of Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia
Source: ClinicalTrials.gov · Last updated 30 Apr 2025
Brief summary (registry, in English)
This study will explore how malnutrition (poor nutrition/diet) and sarcopenia (a condition that causes a loss of muscle and bone mass) affects study participants over the age of 60 with acute myeloid leukemia (AML) who will receive induction chemotherapy (chemotherapy given as the first treatment to help cancer go into remission) and/or cancer drugs as part of standard care for AML. By studying how these nutritional and skeletal factors, doctors leading this study hope to learn how malnutrition and sarcopenia may be able to predict certain outcomes --such as how long study participants with poor nutrition and muscle loss can live after chemotherapy- for older (age 60+) individuals with AML.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 239 (actual)
- First submitted
- 11 Jul 2022
- Start date
- 1 Mar 2023
- Primary completion date
- 18 Apr 2025
- Lead sponsor
- University of Chicago
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT05458258
What you commit to
- Study type: Observational
- Participants enrolled: 239
- From 1 Mar 2023 to the primary completion date, 18 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Presence of a pacemaker or defibrillator.
- Participants who are pregnant at the time of enrollment.
- Anyone unable/unwilling to follow protocol requirements
Who the study is looking for
- Older Adult patients (greater than or equal to 60 years of age)
- New diagnosis of acute myeloid leukemia (AML)
- Receiving induction therapy (intensive or low intensity therapy)
- Willing and able to provide written informed consent
Age in the registry: 60 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Chicago Medicine-Comprehensive Cancer Center Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.